Rotenone adaptation promotes migration and invasion of p53-wild-type colon cancer through lipid metabolism
Clinical and Translational Oncology · 2024
DOI: 10.1007/s12094-024-03785-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Yingying Shi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Maternal and Child Health Hospital of Hubei Province, Wuhan, 430070, China. Hauptthemen laut MEDLINE: Colonic Neoplasms, Rotenone, Cell Movement, Lipid Metabolism. Die Arbeit nennt 45 Literaturangaben. Gefördert von: Scientific Research Fund of Maternal and Child Health Hospital of Hubei Province, Natural Science Foundation of Hubei Province.
Abstract (Originalsprache)
BACKGROUND: The association between mitochondrial dysfunction and multiple metabolic adaptations is increasingly being proven. We previously elucidated that mitochondrial complex I deficiency can promote glycolysis in mut-p53 SW480 cells. However, studies have revealed a phenotype with attenuated glycolysis but enhanced fatty acid oxidation (FAO) in invasive tumors. The interplay between complex I and FAO in carcinogenesis remains obscure. METHODS: The p53 wild-type RKO cells were exposed to rotenone over at least 2 months to acquire rotenone adaptation cells. Then the transwell invasion assays and expression of metabolic enzymes were first detected in rotenone adaptation cells to illustrate whether rotenone adaptation is correlated with the invasion and FAO. The levels of epithelial-to-mesenchymal transition (EMT)-related proteins and acetyl-CoA in rotenone adaptation cells treated with etomoxir (ETO) and acetate were evaluated to verify the role of CPT1A in regulating invasion. Finally, the levels of reactive oxygen species (ROS) were detected. Meanwhile, the invasiveness and histone acetylation levels of rotenone adaptation cells were observed after adding an ROS inhibitor (N-acetyl-L-cysteine NAC) to demonstrate the molecular connection between FAO and invasion during rotenone adaptation. RESULTS: We found long-term exposure to rotenone (a mitochondrial complex I inhibitor) led to EMT and high CPT1A expression in wt-p53 colon cancer. The inhibition of CPT1A suppressed the invasion and reduced histone acetylation, which was rescued by supplementing with acetate. Mechanistically, ROS is crucial for lipid metabolism remodeling. CONCLUSION: Our study provides a novel understanding of the role of complex I in lipid reprogramming facilitating colon cancer invasion and metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Maternal and Child Health Hospital of Hubei Province, Wuhan, 430070, China.
- Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China.
- Department of Oncology, Maternal and Child Health Hospital of Hubei Province, Wuhan, 430070, China. lilinjun00417@126.com.
Förderung
- Scientific Research Fund of Maternal and Child Health Hospital of Hubei Province
- Natural Science Foundation of Hubei Province
Zitieren
APA
Shi, Y., Cao, Z., Ge, L., Lei, L., Tao, D., Zhong, J., Xu, D., Geng, T., Li, X., Li, Z., Xing, S., Wu, X., Wang, Z., & Li, L. (2024). Rotenone adaptation promotes migration and invasion of p53-wild-type colon cancer through lipid metabolism. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03785-x
Vancouver
Shi Y, Cao Z, Ge L, Lei L, Tao D, Zhong J, et al. Rotenone adaptation promotes migration and invasion of p53-wild-type colon cancer through lipid metabolism. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03785-x
BibTeX
@article{Shi2024,
author = {Shi, Yingying and Cao, Zhen and Ge, Ling and Lei, Lin and Tao, Dan and Zhong, Juan and Xu, Dan and Geng, Tao and Li, Xuetao and Li, Ziwei and Xing, Shuaishuai and Wu, Xinyu and Wang, Zhongxu and Li, Linjun},
title = {Rotenone adaptation promotes migration and invasion of p53-wild-type colon cancer through lipid metabolism},
journal = {Clinical and Translational Oncology},
year = {2024},
doi = {10.1007/s12094-024-03785-x}
}
EUVIMED